Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer

Amy K. Leblanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan Wall, Federica Morandi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Palladia TM (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI) approved for treatment of canine mast cell tumors. Receptor tyrosine kinase dysregulation leads to tumor growth, progression, and metastasis. Toceranib's targets include vascular endothelial growth factor receptor (VEGFR-2/Flk-1/KDR), platelet-derived growth factor receptor, and kit. Positron Emission Tomography/Computed Tomography (PET/CT) is used commonly to diagnose, prognosticate, and monitor response to antineoplastic therapy in human patients. In this study, serial PET/CT imaging with 18F-fluorodeoxyglucose ( 18FDG) was used to assess response to toceranib therapy in dogs with measurable solid malignancies. Six tumor-bearing dogs underwent tumor assessment using both standard RECIST criteria and PET/CT prior to and at a median of 5 weeks postinitiation of toceranib treatment. Toceranib was prescribed initially at a target dose 3.25 mg/kg PO q48 h, with subsequent modifications based on observed toxicity. Treatment was continued in patients achieving stable disease with acceptable drug tolerance. One dog was maintained on drug despite dose modification due to toxicity; measurable clinical and image-based responses were seen after 10 weeks of therapy. All others had stable or progressive disease based on clinical restaging and PET/CT at first recheck. Due to discordance with anatomic and metabolic imaging, further studies are needed to investigate the role of molecular imaging in assessment of drug response and identify other potential molecular targets of toceranib.

Original languageEnglish (US)
Pages (from-to)348-357
Number of pages10
JournalVeterinary Radiology and Ultrasound
Volume53
Issue number3
DOIs
StatePublished - May 1 2012

Fingerprint

positron-emission tomography
Pets
computed tomography
pets
Canidae
phosphates
therapeutics
neoplasms
dogs
image analysis
tyrosine
Vascular Endothelial Growth Factor Receptor-2
Neoplasms
phosphotransferases (kinases)
Receptor Protein-Tyrosine Kinases
Dogs
vascular endothelial growth factor receptors
vascular endothelial growth factor receptor-2
toxicity
therapy dogs

All Science Journal Classification (ASJC) codes

  • veterinary(all)

Cite this

Leblanc, A. K., Miller, A. N., Galyon, G. D., Moyers, T. D., Long, M. J., Stuckey, A. C., ... Morandi, F. (2012). Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer. Veterinary Radiology and Ultrasound, 53(3), 348-357. https://doi.org/10.1111/j.1740-8261.2012.01925.x

Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer. / Leblanc, Amy K.; Miller, Ashley N.; Galyon, Gina D.; Moyers, Tamberlyn D.; Long, Misty J.; Stuckey, Alan C.; Wall, Jonathan; Morandi, Federica.

In: Veterinary Radiology and Ultrasound, Vol. 53, No. 3, 01.05.2012, p. 348-357.

Research output: Contribution to journalArticle

Leblanc, Amy K. ; Miller, Ashley N. ; Galyon, Gina D. ; Moyers, Tamberlyn D. ; Long, Misty J. ; Stuckey, Alan C. ; Wall, Jonathan ; Morandi, Federica. / Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer. In: Veterinary Radiology and Ultrasound. 2012 ; Vol. 53, No. 3. pp. 348-357.
@article{5d3794f2f5c6452b9c83298e5bc06575,
title = "Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer",
abstract = "Palladia TM (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI) approved for treatment of canine mast cell tumors. Receptor tyrosine kinase dysregulation leads to tumor growth, progression, and metastasis. Toceranib's targets include vascular endothelial growth factor receptor (VEGFR-2/Flk-1/KDR), platelet-derived growth factor receptor, and kit. Positron Emission Tomography/Computed Tomography (PET/CT) is used commonly to diagnose, prognosticate, and monitor response to antineoplastic therapy in human patients. In this study, serial PET/CT imaging with 18F-fluorodeoxyglucose ( 18FDG) was used to assess response to toceranib therapy in dogs with measurable solid malignancies. Six tumor-bearing dogs underwent tumor assessment using both standard RECIST criteria and PET/CT prior to and at a median of 5 weeks postinitiation of toceranib treatment. Toceranib was prescribed initially at a target dose 3.25 mg/kg PO q48 h, with subsequent modifications based on observed toxicity. Treatment was continued in patients achieving stable disease with acceptable drug tolerance. One dog was maintained on drug despite dose modification due to toxicity; measurable clinical and image-based responses were seen after 10 weeks of therapy. All others had stable or progressive disease based on clinical restaging and PET/CT at first recheck. Due to discordance with anatomic and metabolic imaging, further studies are needed to investigate the role of molecular imaging in assessment of drug response and identify other potential molecular targets of toceranib.",
author = "Leblanc, {Amy K.} and Miller, {Ashley N.} and Galyon, {Gina D.} and Moyers, {Tamberlyn D.} and Long, {Misty J.} and Stuckey, {Alan C.} and Jonathan Wall and Federica Morandi",
year = "2012",
month = "5",
day = "1",
doi = "10.1111/j.1740-8261.2012.01925.x",
language = "English (US)",
volume = "53",
pages = "348--357",
journal = "Veterinary Radiology and Ultrasound",
issn = "1058-8183",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Preliminary evaluation of serial 18fdg-pet/ct to assess response to toceranib phosphate therapy in canine cancer

AU - Leblanc, Amy K.

AU - Miller, Ashley N.

AU - Galyon, Gina D.

AU - Moyers, Tamberlyn D.

AU - Long, Misty J.

AU - Stuckey, Alan C.

AU - Wall, Jonathan

AU - Morandi, Federica

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Palladia TM (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI) approved for treatment of canine mast cell tumors. Receptor tyrosine kinase dysregulation leads to tumor growth, progression, and metastasis. Toceranib's targets include vascular endothelial growth factor receptor (VEGFR-2/Flk-1/KDR), platelet-derived growth factor receptor, and kit. Positron Emission Tomography/Computed Tomography (PET/CT) is used commonly to diagnose, prognosticate, and monitor response to antineoplastic therapy in human patients. In this study, serial PET/CT imaging with 18F-fluorodeoxyglucose ( 18FDG) was used to assess response to toceranib therapy in dogs with measurable solid malignancies. Six tumor-bearing dogs underwent tumor assessment using both standard RECIST criteria and PET/CT prior to and at a median of 5 weeks postinitiation of toceranib treatment. Toceranib was prescribed initially at a target dose 3.25 mg/kg PO q48 h, with subsequent modifications based on observed toxicity. Treatment was continued in patients achieving stable disease with acceptable drug tolerance. One dog was maintained on drug despite dose modification due to toxicity; measurable clinical and image-based responses were seen after 10 weeks of therapy. All others had stable or progressive disease based on clinical restaging and PET/CT at first recheck. Due to discordance with anatomic and metabolic imaging, further studies are needed to investigate the role of molecular imaging in assessment of drug response and identify other potential molecular targets of toceranib.

AB - Palladia TM (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI) approved for treatment of canine mast cell tumors. Receptor tyrosine kinase dysregulation leads to tumor growth, progression, and metastasis. Toceranib's targets include vascular endothelial growth factor receptor (VEGFR-2/Flk-1/KDR), platelet-derived growth factor receptor, and kit. Positron Emission Tomography/Computed Tomography (PET/CT) is used commonly to diagnose, prognosticate, and monitor response to antineoplastic therapy in human patients. In this study, serial PET/CT imaging with 18F-fluorodeoxyglucose ( 18FDG) was used to assess response to toceranib therapy in dogs with measurable solid malignancies. Six tumor-bearing dogs underwent tumor assessment using both standard RECIST criteria and PET/CT prior to and at a median of 5 weeks postinitiation of toceranib treatment. Toceranib was prescribed initially at a target dose 3.25 mg/kg PO q48 h, with subsequent modifications based on observed toxicity. Treatment was continued in patients achieving stable disease with acceptable drug tolerance. One dog was maintained on drug despite dose modification due to toxicity; measurable clinical and image-based responses were seen after 10 weeks of therapy. All others had stable or progressive disease based on clinical restaging and PET/CT at first recheck. Due to discordance with anatomic and metabolic imaging, further studies are needed to investigate the role of molecular imaging in assessment of drug response and identify other potential molecular targets of toceranib.

UR - http://www.scopus.com/inward/record.url?scp=84865096061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865096061&partnerID=8YFLogxK

U2 - 10.1111/j.1740-8261.2012.01925.x

DO - 10.1111/j.1740-8261.2012.01925.x

M3 - Article

VL - 53

SP - 348

EP - 357

JO - Veterinary Radiology and Ultrasound

JF - Veterinary Radiology and Ultrasound

SN - 1058-8183

IS - 3

ER -